Seattle Genetics Presents Adcetris Trials Data

Biopharmaceutical company Seattle Genetics has been busy this weekend, presenting data from a number of trials at the American Society of Clinical Oncology's annual meeting in Chicago.

They include two studies involving lymphoma subtypes:

Retreatment with brentuximab vedotin in CD30-positive hematologic malignancies: a phase II study.

This ongoing phase II trial is investigating patients who previously responded to treatment with Adcetris, then discontinued treatment and subsequently experienced disease progression or relapse.

23 evaluable patients are enrolled, including 16 with Hodgkin lymphoma (HL) and eight with systemic anaplastic large cell lymphoma (sALCL).

Patients had received a median of four prior systemic therapies. 70 percent achieved an objective response, including nine complete remissions (CRs) and seven partial remissions (PRs). Median duration of retreatment objective response was 8.8 months.

Brentuximab vedotin for relapsed or refractory non-Hodgkin lymphoma: preliminary results from a phase II study

This phase II clinical trial involves patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas, including diffuse large B-cell lymphoma (DLBCL), peripheral T-cell lymphoma and other less common lymphoma subtypes (and is still enrolling). The trial was designed to evaluate the activity, duration of response and safety profile of Adcetris in this patient population. 28 patients had been enrolled when the data was analyzed, including 18 with B-cell malignancies and ten with T-cell malignancies. The median number of prior systemic therapies was three. Notably, four of the seven DLBCL patients achieved objective response, including two who had a complete response.

Source: MarketWatch

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap